» Articles » PMID: 8787869

Ciprofloxacin Absorption is Impaired in Patients Given Enteral Feedings Orally and Via Gastrostomy and Jejunostomy Tubes

Overview
Specialty Pharmacology
Date 1996 Jan 1
PMID 8787869
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Twenty-six hospitalized patients participated in a randomized crossover study to evaluate the effect of enteral feedings on ciprofloxacin absorption when given orally or via gastrostomy or jejunostomy tubes. Patients in the oral group received an intact 500-mg ciprofloxacin tablet alone or ciprofloxacin plus three oral doses of Sustacal (240 ml given 8 h before, with, and 4 h after ciprofloxacin administration). Patients with gastrostomy or jejunostomy tubes received 500 mg of crushed ciprofloxacin in 60 ml water via the feeding tube. After a washout period, the patients received ciprofloxacin with a continuous enteral formula (Jevity) given at 60 to 90 ml/h beginning 6 h before drug administration and continuing for 10 h. Serial blood samples were analyzed for ciprofloxacin concentration by high-performance liquid chromatography. The maximum ciprofloxacin concentrations in serum for ciprofloxacin given and for ciprofloxacin plus enteral feeding for the oral, gastrostomy, and jejunostomy groups were (mean +/- standard deviation) 2.59 +/- 1.24 versus 1.43 +/- 0.61 micrograms/ml (P < 0.05), 3.68 +/- 1.36 versus 2.27 +/- 0.67 micrograms/ml (P < 0.05), and 3.78 +/- 1.87 versus 1.45 +/- 0.48 micrograms/ml (P < 0.05), respectively. Corresponding values for area under the concentration-time curve were 13.4 +/- 8.32 versus 9.44 +/- 4.74 micrograms/h/ml (P < 0.05) 15.9 +/- 6.62 versus 7.44 +/- 3.16 (micrograms/h/ml (P < 0.05), and 18.1 +/- 9.37 versus 5.82 +/- 2.63 micrograms.h/ml (P < 0.05). We conclude that enteral feedings given orally or via gastrostomy or jejunostomy tubes resulted in a 27 to 67% reduction in the mean bioavailability of ciprofloxacin in hospitalized patients. The decreased absorption may be clinically important, especially when the enteral feeding is coadministered with ciprofloxacin by the oral and jejunostomy tube routes. Reductions in maximum levels of ciprofloxacin in serum as a result of feedings given via a gastrostomy tube are similar to those following oral administration on an empty stomach, making a clinically important interaction by this route less likely.

Citing Articles

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis.

Burke A, Smith D, Coulter C, Bell S, Thomson R, Roberts J Clin Pharmacokinet. 2021; 60(9):1081-1102.

PMID: 33982266 DOI: 10.1007/s40262-021-01010-4.


Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia.

Tamma P, Conley A, Cosgrove S, Harris A, Lautenbach E, Amoah J JAMA Intern Med. 2019; 179(3):316-323.

PMID: 30667477 PMC: 6439703. DOI: 10.1001/jamainternmed.2018.6226.


Review of antimicrobial use and considerations in the elderly population.

Giarratano A, Green S, Nicolau D Clin Interv Aging. 2018; 13:657-667.

PMID: 29713150 PMC: 5909780. DOI: 10.2147/CIA.S133640.


Addressing Concerns about Changing the Route of Antimicrobial Administration from Intravenous to Oral in Adult Inpatients.

Beique L, Zvonar R Can J Hosp Pharm. 2015; 68(4):318-26.

PMID: 26327706 PMC: 4552233. DOI: 10.4212/cjhp.v68i4.1472.


Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams.

Bolhuis M, Panday P, Pranger A, Kosterink J, Alffenaar J Pharmaceutics. 2013; 3(4):865-913.

PMID: 24309312 PMC: 3857062. DOI: 10.3390/pharmaceutics3040865.


References
1.
Hooper D, Wolfson J . Fluoroquinolone antimicrobial agents. N Engl J Med. 1991; 324(6):384-94. DOI: 10.1056/NEJM199102073240606. View

2.
Yuk J, Nightingale C, Quintiliani R, Yeston N, Orlando 3rd R, Dobkin E . Absorption of ciprofloxacin administered through a nasogastric or a nasoduodenal tube in volunteers and patients receiving enteral nutrition. Diagn Microbiol Infect Dis. 1990; 13(2):99-102. DOI: 10.1016/0732-8893(90)90092-a. View

3.
Midha K, Ormsby E, Hubbard J, McKay G, Hawes E, Gavalas L . Logarithmic transformation in bioequivalence: application with two formulations of perphenazine. J Pharm Sci. 1993; 82(2):138-44. DOI: 10.1002/jps.2600820205. View

4.
Sahai J, Gallicano K, Oliveras L, Khaliq S, Garber G . Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin Pharmacol Ther. 1993; 53(3):292-7. DOI: 10.1038/clpt.1993.24. View

5.
Drusano G, Johnson D, Rosen M, Standiford H . Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993; 37(3):483-90. PMC: 187696. DOI: 10.1128/AAC.37.3.483. View